MAPT and Alzheimer disease: Regarding AD, although extensive research has been carried out on Aβ and tau protein alteration in the cerebrospinal fluid (CSF) and via positron emission tomography (PET), high invasiveness and considerable costs remain a concern, thus preventing the implementation of large-scale population screenings [11].